ONTX
NASDAQOnconova Therapeutics Inc.
Website
News25/Ratings1
Latest news
25 items- SECSEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)10-K/A - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form D filed by Onconova Therapeutics Inc.D - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form DEFA14A filed by Onconova Therapeutics Inc.DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)
- SECOnconova Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- INSIDERNew insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)3/A - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)3/A - Traws Pharma, Inc. (0001130598) (Issuer)
- 13D/GSEC Form SC 13D filed by Onconova Therapeutics Inc.SC 13D - Traws Pharma, Inc. (0001130598) (Subject)
- INSIDERRedfield Robert was granted 97,500 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERPauza Charles David was granted 97,500 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERCautreels Werner was granted 200,000 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSavchuk Nikolay was granted 2,664,869 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERDukes Iain D. was granted 1,779,337 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Viriom, Inc. claimed ownership of 1,645,100 shares (SEC Form 3)3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Orbimed Advisors Llc claimed ownership of 885,532 shares (SEC Form 3)3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Redfield Robert3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pauza Charles David3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cautreels Werner3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Tpav, Llc claimed ownership of 885,532 shares (SEC Form 3)3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Savchuk Nikolay3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dukes Iain D.3 - Traws Pharma, Inc. (0001130598) (Issuer)
- NEWSOnconova Therapeutics shares are trading lower after the company announced that it entered into a definitive merger agreement to acquire 100% of Trawsfynydd's outstanding equity interests.
- PRTraws Pharma Announces New Employee Inducement GrantsNEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws", the "Company"))) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the "Merger"). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock. One-quarter (1/4) of the shares subject to each restricted stock equity awar
- NEWSOnconova Therapeutics, Inc. And Trawsfynydd Therapeutics, Inc. Announce All-Stock Business Combination, Under Agreement, Onconova Acquired 100% Of Trawsfynydd's Outstanding Equity Shares With A Combined Fully Diluted Equity Value Of $132M; In Connection, Traws Will Raise $14M In Committed Private Placement Financing
- PROnconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology CompanyClosing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir in 2024, with first top-line read-outs expected in H2 2024Traws Pharma to be led by incoming CEO, Werner Cautreels, Ph.D. Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) alo
- SECSEC Form 10-K filed by Onconova Therapeutics Inc.10-K - Onconova Therapeutics, Inc. (0001130598) (Filer)